tirzepatide compound mexico Eli Lilly plans to launch weight-loss drug in emerging markets this year hormone GLP Compounded Tirzepatide Weight Management Program

medscape.com Mondelez chief executive, 2025 investor conference, reported in trade press: estimated GLP-1 medications would have a 1 to 1.5 percent impact on volume over ten years, citing access limits and high discontinuation

The Phase 2 trial data showed nausea in roughly 28% of patients at the 12mg dose, diarrhea in 24%, vomiting in 17%, and constipation in 11%

Overweight or obesity is a real problem among the general population, with many struggling with weight management and weight loss

TUNEL and flow cytometry analyses demonstrated an inhibitory role of liraglutide in liver apoptosis in vivo and in vitro